[Effects of administration of 50 mg heparan sulfate tablets to patients with varicose dilatation of the hemorrhoid plexus (hemorrhoids)].
An experimental clinical study was performed using heparan sulfate in order to ascertain the effects of the drug in the treatment of 2nd or 3rd degree varicose dilatation of the hemorrhoid plexus. Forty female patients, mean age 37 years and suffering from varicose dilatation of the hemorrhoid plexus, were enrolled in the study. The study was carried out in an open comparison with oxerutin using parallel groups with random access. After a run-in period of 3 days, 20 patients commenced treatment with 1 50 mg tablet of heparin sulfate 3 times daily, whereas the other 20 patients were given 1,500 mg oxerutin tablet again 3 times daily. Subsequently, treatment was continued at the following doses: 1 50 mg tablet of heparin sulfate twice a day, and 1,500 mg tablet of oxerutin twice a day, for a duration of two weeks. At pre-established times (before treatment, after 1 week, after 2 weeks), a standard questionnaire was filled in relating to each patient in order to evaluate the efficacy and tolerability of treatment. No adverse or undesirable effects were reported. Each participant was also put on a personalized and computerised diet with the same fibre intake. 55% of patients treated with oxerutin reported persistent moderate or intense pain caused by defecation compared to 45% of the group treated with heparan sulfate. Both drugs induced the remission of skin rash and itching. Compared to the control drug, heparan sulfate was more efficacious in relation to the normalisation of hyperemia and mucoid secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
De Cecco
L
L
II Clinica Ostetrica e Ginecologica, Ospedale San Martino, Genova.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006484:Hemorrhoids / Q000188:drug therapy*; D006497:Heparan Sulfate / Q000008:administration & dosage*; D006801:Humans; D006896:Hydroxyethylrutoside / Q000008:administration & dosage / Q000031:analogs & derivatives; D011897:Random Allocation; D013607:Tablets; D014648:Varicose Veins / Q000188:drug therapy*
D006497:Heparan Sulfate; D006896:Hydroxyethylrutoside; D013607:Tablets; C005865:troxerutin
Effetti della somministrazione di eparan-solfato confetti da 50 mg in pazienti affetti da dilatazione varicosa del plesso emorroidario (emorroidi).